Expand PGEN Menu
PGEN MENU

PGEN Latest Press Releases

-- August 4, 2026 --

Precigen Reports Second Quarter 2026 Financial Results Highlighted by Accelerating PAPZIMEOS Revenue Growth PRNewswire 4:01 PM

-- July 21, 2026 --

Precigen to Announce Second Quarter 2026 Financial Results and Provide Business Updates on August 4 PRNewswire 8:01 AM

-- June 15, 2026 --

Precigen Gains Advantage as PAPZIMEOS Granted Orphan Drug Exclusivity by FDA; Long-Term Data From Clinical Study Encouraging ACCESS Newswire 6:40 AM

-- June 11, 2026 --

Precigen and the Recurrent Respiratory Papillomatosis Foundation Recognize International RRP Awareness Day by Elevating Patient and Community Voices PRNewswire 8:00 AM

-- May 30, 2026 --

Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years PRNewswire 2:30 PM

-- May 27, 2026 --

Precigen Receives Orphan Drug Exclusivity for PAPZIMEOS (zopapogene imadenovec-drba) in the United States PRNewswire 7:00 AM

-- May 26, 2026 --

Precigen to Participate in Fireside Chats with J.P. Morgan and at the Goldman Sachs 47th Annual Global Healthcare Conference PRNewswire 8:05 AM

-- May 13, 2026 --

Precigen Reports First Quarter 2026 Financial Results and Business Updates PRNewswire 4:05 PM

-- May 7, 2026 --

Precigen to Announce First Quarter 2026 Financial Results and Provide Business Updates on May 13 PRNewswire 4:05 PM

-- April 7, 2026 --

Precigen Reports 'Robust Uptake' of New Drug for Rare Respiratory Disease; First Quarter Revenue Expected to Top $18 Million ACCESS Newswire 7:00 AM

-- March 30, 2026 --

Precigen to Participate in a Fireside Chat with H.C. Wainwright on March 31 PRNewswire 8:30 AM

-- March 25, 2026 --

Precigen Reports Full Year 2025 Financial Results and Business Updates PRNewswire 4:05 PM

-- March 11, 2026 --

Precigen to Announce Full Year 2025 Financial Results and Provide Business Updates on March 25 PRNewswire 4:05 PM
Market Data Delayed 15 Minutes